Journal article
GP73, a resident Golgi glycoprotein, is a novel serum marker for hepatocellular carcinoma
Journal of hepatology, v 43(6), pp 1007-1012
2005
PMID: 16137783
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
Golgi protein-73 (GP73) is up-regulated in hepatocellular carcinoma (HCC). The aims of this study were to determine if GP73 is detected in the serum, and to establish the sensitivity and specificity of serum GP73 for diagnosing HCC.
Serum GP73 was detected by immunoblots and quantified by densitometric analysis.
A total of 352 patients were studied. Serum GP73 levels were significantly higher in patients with HCC compared to those with cirrhosis (
P<0.001). GP73 had a sensitivity of 69% and a specificity of 75% at the optimal cutoff point of 10 relative units, with an area under the receiver operating curve of 0.79 vs. 0.61 for AFP (
P=0.001). GP73 levels had significantly higher sensitivity (62%) than AFP (25%) for diagnosing early HCC (
P<0.0001). Moreover, GP73 levels were elevated in the serum of 57% (32/56) of individuals with HCC who had serum AFP levels less than 20
ng/ml.
Higher levels of GP73 can be found in the serum of patients with HCC than of those without. GP73 was better than AFP for the diagnosis of early HCC. Further validation studies are needed to confirm the role of GP73 in the early detection of HCC.
Metrics
Details
- Title
- GP73, a resident Golgi glycoprotein, is a novel serum marker for hepatocellular carcinoma
- Creators
- Jorge A Marrero - Division of Gastroenterology, University of Michigan Medical Center, 3912 Taubman Center, Ann Arbor, MI 48109-0362, USAPatrick R Romano - Department of Microbiology and Immunology, Drexel Institute for Biotechnology and Virus Research, Drexel University College of Medicine, Doylestown, PA 18901, USAOlga Nikolaeva - Department of Microbiology and Immunology, Drexel Institute for Biotechnology and Virus Research, Drexel University College of Medicine, Doylestown, PA 18901, USALaura Steel - Department of Microbiology and Immunology, Drexel Institute for Biotechnology and Virus Research, Drexel University College of Medicine, Doylestown, PA 18901, USAAnand Mehta - Department of Microbiology and Immunology, Drexel Institute for Biotechnology and Virus Research, Drexel University College of Medicine, Doylestown, PA 18901, USAClaus J Fimmel - Division of Gastroenterology and Hepatology, Saint Louis VA Medical Center, Saint Louis University School of Medicine, St Louis, MO 631110-0250, USAMary Ann Comunale - Department of Microbiology and Immunology, Drexel Institute for Biotechnology and Virus Research, Drexel University College of Medicine, Doylestown, PA 18901, USAAnthony D'Amelio - Hepatitis B Foundation/Institute for Hepatitis and Virus Research, Doylestown, PA 18901, USAAnna S Lok - Division of Gastroenterology, University of Michigan Medical Center, 3912 Taubman Center, Ann Arbor, MI 48109-0362, USATimothy M Block - Department of Microbiology and Immunology, Drexel Institute for Biotechnology and Virus Research, Drexel University College of Medicine, Doylestown, PA 18901, USA
- Publication Details
- Journal of hepatology, v 43(6), pp 1007-1012
- Publisher
- Elsevier
- Resource Type
- Journal article
- Language
- English
- Academic Unit
- Microbiology and Immunology
- Web of Science ID
- WOS:000234059700014
- Scopus ID
- 2-s2.0-27744539432
- Other Identifier
- 991014878165704721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Collaboration types
- Domestic collaboration
- Web of Science research areas
- Gastroenterology & Hepatology